Paliperidone is risperidone's 9-hydroxy active metabolite, marketed as its own drug. The pharmacology is essentially identical to risperidone — same D2 + 5-HT2A profile, same prolactin elevation, same dose-dependent EPS pattern. The differentiator is the formulation strategy, and what paliperidone offers is the most comprehensive long-acting injectable spectrum in psychiatry.
- Class
- Second-generation antipsychotic
- Mechanism
- Same pharmacology as risperidone's 9-OH metabolite: D2 + 5-HT2A antagonism plus alpha-1/2 effects
- Typical dose
- Oral 3-12 mg/day. LAI: Invega Sustenna (monthly), Trinza (every 3 months), Hafyera (every 6 months)
- Half-life
- Oral ~23 hours; LAI ranges from weeks to months
- FDA indications
- Schizophrenia, schizoaffective disorder
- Key adverse effects
- Similar to risperidone: hyperprolactinemia (prominent), EPS (dose-dependent), weight gain (moderate), sedation, QTc prolongation
Black box: Increased mortality in elderly patients with dementia-related psychosis
LAI formulations are paliperidone's defining contribution — monthly, every-3-months, every-6-months options. Adherence transformation possible. Renal dose adjustment important (cleared primarily renally vs. risperidone primarily hepatic).
Paliperidone Sustenna — monthly intramuscular injection. Established LAI delivery, well-studied, widely covered by insurance, the most commonly used of the paliperidone LAIs.
Paliperidone Trinza — every three months. Patient must first stabilize on monthly Sustenna for at least four months, then transition. The longer interval reduces injection frequency from twelve times a year to four. For stable patients, that's a meaningful quality-of-life improvement and a substantial adherence support.
Paliperidone Hafyera — every six months. Patient must first stabilize on Trinza, then transition. Two injections per year. For severely adherence-limited schizophrenia, this is transformative — daily medication decisions essentially disappear from the patient's life, with the medication itself delivered twice yearly.
The trade-off across the LAI spectrum is the slow washout if adverse effects develop. Six-month formulations cannot be quickly reversed if EPS, prolactin symptoms, or other problems emerge. The patient must demonstrate stability on shorter-interval formulations before extending. Paliperidone is renally cleared — dose adjustment in CKD is more important than for hepatically cleared agents.
- Cost
- Sustenna ~$1,800-2,400/month. Trinza ~$5,800/q3mo. Hafyera ~$11,000/q6mo. Oral generic ~$200/month.
- Generic status
- Oral generic since 2019. LAIs brand-only.
- Formulary typical
- LAIs: specialty tier, universally require PA. Oral generic Tier 2.
- Access friction
- Janssen patient support program (Janssen CarePath) is the navigator. Most patients access through Medicaid where coverage is reliable; commercial coverage variable. Specialty pharmacy and clinic buy-and-bill both used.
Prescriber tip: Plan the access pathway before the conversation with the patient — knowing whether their insurance covers and at what cost shapes whether you offer Sustenna vs Trinza vs Hafyera. Janssen CarePath enrollment supports both insurance and patient cost.
Oral paliperidone exists but is less commonly used than oral risperidone given the metabolite/parent relationship. The LAI spectrum is where paliperidone has reshaped schizophrenia care for the population that needed adherence support most.
Paliperidone is the active metabolite of risperidone, with pharmacokinetic refinements — extended-release oral and long-acting injectable formulations — as its main advantage.
Mechanism note: Paliperidone is risperidone's active metabolite repackaged for better kinetics — its real value is the long-acting injectable range, including the 6-monthly formulation for adherence-critical patients.